Navigation Links
Frost & Sullivan to Discuss Investment Patterns in the Healthcare Industry in Free Webinar
Date:10/9/2009

MOUNTAIN VIEW, Calif., Oct. 9 /PRNewswire/ -- The Business & Financial Services practice at Frost & Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation entitled Investment Patterns in the Healthcare Industry - An Analysis to be held on Tuesday, October 13, 2009 at 8:00 a.m. PT.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

The past year has ushered in a variety of changes to the global healthcare industry. In response to recessionary environments, participants are preparing for intense competition, cost control measures, and jockeying for optimal positioning within the market. Borrowing patterns, OIS-LIBOR rates, stock market performances for various industries and federal interest rates have all re-aligned to suit the market conditions.

This briefing will benefit private equity companies, venture capitalists, hedge funds, asset management companies, investment bankers, universities, corporate clients with an interest in healthcare, along with other retail investors. Highlights of this event include analyses of debt patterns, equity investments, and loans spanning across five major sectors in the global healthcare industry.

The recession has had an adverse impact on funding patterns in the healthcare industry. Improvement in the economic situation coupled with President Obama's stimulus package is expected to serve as a boost to the investments in the defensive healthcare sector. In addition, the recovery in the stock markets is expected to see more funds being raised by companies in the way of equity transactions.

To participate, please email Johanna Haynes at johanna.haynes@frost.com with the following information: your full name, title, company name, telephone number, e-mail address, city, state, and country. Upon receipt of the above information, a registration link will be emailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting, and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates, and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.

    Contact:

    Johanna Haynes
    Corporate Communications - North America
    P: 210.247.3870
    F: 210.348.1003
    E: johanna.haynes@frost.com

    http://www.frost.com

SOURCE Frost & Sullivan


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
2. Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership
3. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
4. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
5. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
6. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
7. MedApps Receives Prestigious Frost & Sullivan Award
8. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
9. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
10. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
11. Therapy Could Save Limbs After Frostbite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: